Endocrine therapy for the treatment of postmenopausal women with breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 2, 2009, Pages 187-198

  Harichand Herdt, Seema ^a   Zelnak, Amelia ^a   O'Regan, Ruth ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Anastrozole; Aromatase; Estrogen; Exemestane; Fulvestrant; Hormone therapy; Letrozole; Raloxifine; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; ESTROGEN; EXEMESTANE; FULVESTRANT; GEFITINIB; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; PLACEBO; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FRAGILITY FRACTURE; HEART DISEASE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LUNG EMBOLISM; MENOPAUSAL SYNDROME; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT DURATION; UTERUS CANCER; VAGINA BLEEDING; VEIN THROMBOSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN;

EID: 64349115050     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.2.187     Document Type: Review

References (105)

1. Brock R. The Life and Works of Astley Cooper. E&S Livingston Ltd, London, UK (1952).
2. Beatson G. On the treatment of inoperable cases of the mammary: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-165 (1986).
3. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg. 115(6), 1192-1200 (1942).
4. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer. J. Clin. 22(4), 232-240 (1972).
5. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12(2), 134-141 (1952).
6. Dodds E, Lawson W, Noble RL. Biological effects of the synthetic oestrogen substance 4:4-dihydroxy a β-diethylstilbene. Lancet 1, 1389-1391 (1938).
7. Jensen EV, Block GE, Smith S et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst. Monogr. 34, 55-70 (1971).
8. Toft D, Shyamala G, Gorski J. A receptor molecule for estrogens: studies using a cell-free system. Proc. Natl Acad. Sci. USA 57(6), 1740-1743 (1967).
9. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer. 25(2), 270-275 (1971).
10. Winer EP, Hudis C, Burnstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol. 20(15), 3317-3327 (2002).
11. Judd HL, Judd GE, Lucas WE et al. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39(6), 1020-1024 (1974).
12. Richards JS, Hickey GK, Chen SA et al. Hormonal regulation of estradiol biosynthesis, aromatase activity, and aromatase mRNA in rat ovarian follicles and corpora lutea. Steroids 50(4-6), 393-409 (1987).
13. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348(24), 2431-2442 (2003).
14. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev. Anticancer Ther. 2(2), 151-160 (2002).
15. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114), 1451-1467 (1998).
16. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
17. Belfiglio M, Valentini M, Pellegrini F et al. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 104(11), 2334-2339 (2005).
18. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J. Natl Cancer Inst. 93(6), 456-462 (2001).
19. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Natl Cancer Inst. 88(21), 1543-1549 (1996).
20. Delozier T, Speilmann M, Mace-Lesec'h J et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J. Clin. Oncol. 18(20), 3507-3512 (2000).
21. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93(9), 684-690 (2001).
22. Stewart HJ, Forest AP, Everington D et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br. J. Cancer 74(2), 297-299 (1996).
23. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003).
24. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
25. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249-258 (2005).
26. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005).
27. Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat. Rep. 60(10), 1409-1419 (1976).
28. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
29. Cuzick, J Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336), 817-824 (2002).
30. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122), 98-101 (1998).
31. Veronesi U, Maissonneuve P, Rotmensz N et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J. Natl Cancer Inst. 95(2), 160-165 (2003).
32. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354), 296-300 (2003).
33. Shen Y, Costantino JP, Qin J. Tamoxifen Chemoprevention treatment and time to first diagnosis of estrogen receptor - negative breast cancer. J. Natl Cancer Inst. 100, 1448-1453 (2008).
34. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326(13), 852-856 (1992).
35. Kristensen B, Ejlertsen B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol. 12(5), 992-997 (1994).
36. Bruning PF, Bonfrer JM, Hart AA et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer 58(4), 497-499 (1988).
37. Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst. 86(20), 1534-1539 (1994).
38. Saarto T, Blomqvist C, Enholm C et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 14(2), 429-433 (1996).
39. Anker G, Lonning PE, Ueland PM et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int. J. Cancer. 60(3), 365-368 (1995).
40. Carstensen J, Rosell J, Bengtsson N-O et al. Prolonged tamoxifen therapy: effects on contralateral breast cancer, endometrial cancer and cardiovascular mortality. Breast Cancer Res. Treat. 82(Suppl. 1), (2003) (Abstract 425).
41. Vogel CL, Shermano I, Schoenfelder J et al. Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 11(2), 345-350 (1993).
42. Pyrhonen S, Ellmen J, Vuorinen J et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat. 56(2), 133-143 (1999).
43. Holli K, Valavaara R, Blanco G et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with nodepositive breast cancer. Finnish Breast Cancer Group. J. Clin. Oncol. 18(20), 3487-3494 (2000).
44. Buzdar AU, Marcus C, Holmes F et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45(5), 344-345 (1988).
45. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87(8), 3609-3617 (2002).
46. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 65(2), 125-134 (2001).
47. Fisher B, Constantino JP, Wickerham DL et al., Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97(22), 1652-1662 (2005).
48. Tan-Chiu E, Wang J, Constantino JP et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J. Natl Cancer Inst. 95(4), 302-307 (2003).
49. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9), 1802-1810 (2003).
50. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25(5), 486-492 (2007).
51. Vogel VG, Constatntino JP, Dickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2727-2741 (2006).
52. Santen RJ, Worgul TJ, Lipton A et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Intern. Med. 96(1), 94-101 (1982).
53. Plowman PN, Nicholson RI, Walker KJ. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br. J. Cancer 54(6), 903-909 (1986).
54. Blamey RW, Jonat W, Kaufmann M et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer 28A(4-5), 810-814 (1992).
55. Dixon AR, Robertson JF, Jackson L et al. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br. J. Cancer 62(5), 868-870 (1990).
56. Harvey HA, Lipton A, Max DT et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J. Clin. Oncol. 3(8), 1068-1072 (1985).
57. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol. 26(10), 1671-1676 (2008).
58. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer 6(1), 75-92 (1999).
59. Suzuki T, Miki Y, Ohuchi N et al. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 15(4), 270-277 (2008).
60. Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19(14) 3357-3366 (2001).
61. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer 83(6), 1142-1152 (1998).
62. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol. 18(7), 1399-1411 (2000).
63. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21(11), 2101-2109 (2003).
64. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19(10), 2596-2606 (2001).
65. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9), 2247-2258 (2001).
66. Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am. J. Clin. Oncol. 26(3), 317-322 (2003).
67. Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 39(12), 1684-1689 (2003).
68. Nabholtz, JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 18(22), 3758-3767 (2000).
69. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 14(9), 1391-1398 (2003).
70. Bertelli G, Garrone O, Merlano M et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69(6), 471-477 (2005).
71. Iaffaioli RV, Formato R, Tortoriello A et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br. J. Cancer 92(9), 1621-1625 (2005).
72. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol. 18(11), 2234-2244 (2000).
73. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002).
74. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9(1), 45-53 (2008).
75. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005).
76. Mouridsen H, Giobbie-Hurder A, Mauriac L et al. BIG I-98: a randomized double-blind Phase III study of letrozole and tamoxifen given in sequence as adjuvant therapy for postmenopausal women with receptor-positive cancer. Cancer Res. 69(Suppl. 2), S66 (2009).
77. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455-462 (2005).
78. Jakesz R, Gnant M, Griel R et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res. 69(Suppl. 2), 67S (2009).
79. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350(11), 1081-1092 (2004).
80. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559-570 (2004).
81. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev. 1, CD000486 (2001).
82. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14(10), 2738-2746 (1996).
83. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97(17), 1262-1271 (2005).
84. Goss PE, Ingle JN, Martino S et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J. Clin. Oncol. 25(15), 2006-2011 (2007).
85. Goss, PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349(19), 1793-1802 (2003).
86. Ingle JN, Tu D, Pater JL et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res. Treat. 99(3), 295-300 (2006).
87. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23(16 Suppl.), S527 (2005).
88. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr. Relat. Cancer 7(1), 17-28 (2000).
89. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 20(16), 3386-3395 (2002).
90. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 22(9), 1605-1613 (2004).
91. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 26(10), 1664-1670 (2008).
92. Perey L, Parideans R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 18(1), 64-69 (2007).
93. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
94. Paik S, Shak S, Tang G et al. Expression of the 21 gene recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B14 and chemotherapy in NSABP study B-20. Breast Cancer Res. Treat. 88(Suppl. 15), S24 (2004).
95. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
96. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
97. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355(6), 560-569 (2006).
98. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24(2), 85-95 (1992).
99. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 11(13), 4741-4748 (2005).
100. Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium. TX, USA, 14-17 December 2006 (Abstract 3).
101. Schafer JM, Bentrem DJ, Takei H et al. A mechanism of drug resistance to tamoxifen in breast cancer. J. Steroid Biochem. Mol. Biol. 83(1-5), 75-83 (2002).
102. Kaklamani VG, Cicconi J, Gradishar W et al. Increased HER2 expression in women with recurrent ER positive breast cancer. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18S), 10516 (2007).
103. Cristofanilli M, Valero V, Mangalik A et al. A Phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings. J. Clin. Oncol. 26(18 Suppl.), S1012 (2008).
104. Dickler M. A pilot Phase II trial of bevacizumab and letrozole for hormone refractory metastatic breast cancer. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. Washington, DC, USA, 5-7 September 2008.
105. Winer EP, Hudis C, Burnstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23(3), 619-629 (2005).